J&J Wins Full FDA Approval for Rybrevant, Chemo Combo in NSCLC

The FDA on Friday approved Johnson & Johnson’s bispecific antibody Rybrevant (amivantamab-vmjw) for the first-line treatment of locally advanced non-small cell lung cancer in combination with carboplatin and pemetrexed.